How Ovarian Tumors Evade Immune System Science Daily (press release) - Disrupted or stalled T cell action has been known to play a key role in the spread of several kinds of cancer, the scientists say. ...
Prostate Cancer Spurs New Nerves Science Daily (press release) - When prostate cancer cells overproduce semaphorin 4F, new nerves result. Blocking semaphoring 4F prevents the growth of new nerves. ...
Military tribunal splits first Guantanamo Bay verdict Minneapolis Star Tribune, MN - The Bush administration seized on the acquittal on the conspiracy charges to defend the tribunal system against accusations that it was politicized and ...
Al Qaeda Shifting Tactics, Finding New Recruits Family Security Matters, NJ - Terrorist cells in places such as Ohio , Illinois , California , New York and New Jersey targeted the US government, the military and critical ...
Adds to Muslim 'burden of suspicion', Uighurs say Al-Arabiya, United Arab Emirates - Aug 5, 2008 This year separatist leaders had ordered a string of attacks and sent bomb-making and poisoning manuals to cells in China, Shi said. ...
'?500k' to family of mad Rad The Sun, UK - Aug 5, 2008 Former Yugoslavian president Slobodan Milosevic?s war crimes trial had dragged on that long when he died of a heart attack in his cell in 2006. ...
Lawyer says Radovan Karadzic plans to defend himself at UN war ... International Herald Tribune, France - Jul 23, 2008 The four-year trial ended in 2006 without a verdict when he died in his cell of a heart attack. Vojislav Seselj, leader of the ultranationalist Serbian ...
Jonathan Kay on the 10th anniversary of the 1998 US embassy ... National Post, Canada - Aug 3, 2008 Lesson #2: Even in very poor and chaotic areas of the world, Western powers can defend their assets from terrorist attacks. The 1998 attacks were a massive ...
HIV/AIDS Will Remain a Critical Issue for Years to Come eFluxMedia - Aug 5, 2008 The virus mutates rapidly, hides from the immune system, and targets and destroys the immune system cells that successfully defend against most other ...
Source: Google News
Intrinsic immunity: a front-line defense against viral attack - PD Bieniasz - Nature Immunology, 2004 - nature.com ... target of another previously unknown host defense factor that ... predicted is by evolving
multiple ways to attack. ... Thus, cells may have evolved, in effect, TRIM ...
Immunocytochemistry of plant defense mechanisms induced upon microbial attack - N Benhamou - Microscopy Research and Technique, 1995 - doi.wiley.com ... by which plant cells re- spond to attack by pathogens. Research in plant pathol-
ogy and molecular biology has focused on plant defense reactions for two quite ...
Immunology: Tumor Cells Fight Back to Beat Immune System - N Williams - Science, 1996 - sciencemag.org ... They wondered whether tumors in patients might be able to defend themselves against attack from T cells or other effector cells of the immune system by ...
Cross talk between signaling pathways in pathogen defense - BN Kunkel, DM Brooks - Current Opinion in Plant Biology, 2002 - Elsevier ... plants to fine-tune their defense responses, such ... of SA signaling in response to attack by necrogenic pathogens, which utilize cell-death inducing ...
Seaweed resistance to microbial attack: A targeted chemical defense against marine fungi - J Kubanek, PR Jensen, PA Keifer, MC Sullards, DO … - Proceedings of the National Academy of Sciences, 2003 - National Acad Sciences ... Human colon tumor cell line HCT-116 ... fungal hyphae into healthy algal tissues and defend damaged tissues ... L. thalassiae, are believed to attack primarily algal ...
Source: Google Scholar
FAK's interaction with VEGFR-3 helps cancer cells defend against attack
The cells churn out an enzyme that bonds with a protein, creating a protective barrier that deflects damage from radiation or chemotherapy and promotes tumor cell survival. But in laboratory experiments, researchers at University of Florida ( UF ) were able to block the union, and the malignant cells died.
The findings are opening new avenues of research that could lead to improved cancer therapies, the researchers reported in the journal Cancer Research.
" We have found a gene called focal adhesion kinase which is produced at very high levels in human tumors, and our work has shown this makes the tumors more likely to survive as they spread throughout the body and grow," said William G. Cance, at the University of Florida Shands Cancer Center." It also makes them more resistant to our attempts to kill them. And we're trying to understand exactly why this gene, which is a small enzyme molecule, is very intimately associated with tumor cell survival."
Focal adhesion kinase, or FAK, is commanding increasing attention and has spawned a flurry of research designed to develop new drug therapies, said Cance, who is known internationally for his genetic investigations of tumor survival. These medicines would prevent FAK from linking with the protein known as vascular endothelial growth factor receptor 3, or VEGFR-3. The protein is tied to the growth of channels in the lymph system that serve as cellular superhighways for cancer spread and is found in breast, colon and thyroid tumors.
Cance and colleagues were the first to pull FAK out of human tumors and to show that human cancers make the molecule in large quantities. In 1996, the team was the first to show that if a tumor is prevented from producing the enzyme it dies. The scientists also have identified some protein receptors FAK binds to; VEGFR-3 is the latest they've discovered and represents a "hot area for developing therapeutics," Cance said.
" We've shown that if you disrupt this interaction - if you block the binding of these two proteins - the tumor cells are more prone to being killed," he said.
UF researchers identified FAK's interaction with VEGFR-3 in cell cultures of human breast cancer. Breast cancers that pump out high volumes of FAK and VEGFR-3 are more aggressive tumors, Cance said. The scientists were able to block FAK from binding with VEGFR-3 by introducing a different protein that stopped cancer cells from dividing and caused them to die but spared normal breast cells.
" FAK is a critical molecule, and in the future different ways of targeting either the enzyme itself or targeting the binding between these various proteins will have a major impact on cancer, I believe," Cance said. " We think it's one of the Achilles' heels for tumor cells and you can disrupt it in a number of different ways. For example, we might be able to design drugs that mimic this area of binding and disrupt it in patients."
Because normal cells generate much lower levels of FAK than tumor cells do, treatments could be developed to target FAK and VEGFR-3 at dosages markedly less toxic to healthy tissues yet lethal to cancer.
" We have a therapeutic window," said Cance, the study's senior investigator. " In normal cells we've shown you can knock it out and cells can still resist the loss of expression of focal adhesion kinase, whereas the tumor cells use it as one of their major proteins for survival."
" We take our patients, we look at their tumors and we try to find clues to why their tumors grow, why their tumors spread, and we look at the various genes and proteins that make their tumors what they are," Cance said. "So from the patient's standpoint, the more that we can characterize their tumor and understand why it behaves like it does, the greater chance we'll then be able to go back to the patient with therapeutics, and that laboratory bench to bedside is what our research is all about."
